DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis – with future targets for further and new patient groups and segments.

Quotes for DanCann Pharma A/S

Right Now

+/-
0.038
%
4,61%
Latest
0.862
High
1.238
Low
0.85
Volume
313 401
Turnover (DKK)
301 367
Market Value (MDKK)
24,5
Time (Latest trade)
2022-12-02 16:35

Board

CEO

  • Jeppe Krog Rasmussen

Chairperson of the Board

  • Carsten Trads

Board

  • Jeppe Krog Rasmussen
  • Alexander Schoeneck
  • Christian Carlsen
  • Tue Østergaard

Largest Owners

Name Capital % Votes % Date
Jeppe Krog Rasmussen 20,19 20,19 2022-06-30
Sellers of CannGros ApS 7,85 7,85 2021-10-05
Alexander Schoeneck 6,21 6,21 2022-06-30
Futur Pension 5,56 5,56 2021-09-30
Morten Martinsen 1,41 1,41 2021-12-30
Hansen & Nytoft Invest Aps 1,34 1,34 2021-08-19
Vavi Invest Aps 0,88 0,88 2021-08-19
John Frellsen 0,60 0,60 2021-07-26
JBJensen ApS 0,53 0,53 2021-08-19
Per Wester 0,50 0,50 2021-08-19
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

Key Numbers

*Compiled data from Millistream